Avoid the stress of overpaying for a stock or missing an opportunity by using the right tools and insights to evaluate ClearPoint Neuro, Inc. before investing.

In this article, we go over a few key elements for understanding ClearPoint Neuro, Inc.’s stock price such as:

• ClearPoint Neuro, Inc.’s current stock price and volume
• Why ClearPoint Neuro, Inc.’s stock price changed recently
• Upgrades and downgrades for CLPT from analysts
• CLPT’s stock price momentum as measured by its relative strength

About ClearPoint Neuro, Inc. (CLPT)

Before we jump into ClearPoint Neuro, Inc.’s stock price, history, target price and what caused it to recently rise, let’s take a look at some background.

ClearPoint Neuro, Inc., a commercial-stage medical device company, focuses on the development and commercialization of platforms for performing minimally invasive surgical procedures in the brain in the United States. The company offers ClearPoint systems, such as ClearPoint hardware, which includes head fixation frame, computer workstation, and in-room monitor; and ClearPoint disposables, which consist of SmartFrame trajectory device, a hand controller and related accessories, and its SmartFlow Neuro cannula. It also provides ClearPoint software, which guides the physician in surgical planning, device alignment, navigation to the target, and procedure monitoring; ClearPoint Prism Neuro laser therapy system to necrotize or coagulate soft tissue; and IRRAflow system, an active fluid exchange platform. In addition, the company offers consulting services to its pharmaceutical and other medical technology partners, such as benchtop testing, preclinical studies, clinical trial support, regulatory consultation, and translation from the preclinical to the clinical setting. It has licenses and collaboration agreements with Koninklijke Philips N.V., UCB Biopharma SRL, Clinical Laserthermia Systems AB, University of California, San Francisco, and NE Scientific, LLC. The company was formerly known as MRI Interventions, Inc. and changed its name to ClearPoint Neuro, Inc. in February 2020. ClearPoint Neuro, Inc. was incorporated in 1998 and is headquartered in Solana Beach, California.

Want to learn more about ClearPoint Neuro, Inc.’s stock? Click the button below to subscribe to A+ Investor and get access to everything you need to know about ClearPoint Neuro, Inc..

ClearPoint Neuro, Inc.’s Stock Price as of Market Close

As of May 04, 2026, 9:45 AM, CST, ClearPoint Neuro, Inc.’s stock price was $11.500.

ClearPoint Neuro, Inc. is up 1.14% from its previous closing price of $11.370.

During the last market session, ClearPoint Neuro, Inc.’s stock traded between $11.330 and $11.550. Currently, there are approximately 28.85 million shares outstanding for ClearPoint Neuro, Inc..

ClearPoint Neuro, Inc.’s trailing earnings per share are negative, so the stock does not have a meaningful P/E ratio. We suggest investors evaluate other financial metrics to understand its overall valuation.

ClearPoint Neuro, Inc. Stock Price History

ClearPoint Neuro, Inc.’s (CLPT) price is currently up 2.86% so far this month.

During the month of May, ClearPoint Neuro, Inc.’s stock price has reached a high of $11.550 and a low of $11.070.

Over the last year, ClearPoint Neuro, Inc. has hit prices as high as $30.100 and as low as $8.270. Year to date, ClearPoint Neuro, Inc.’s stock is down 15.94%.

Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions

What Caused ClearPoint Neuro, Inc. Stock’s Price to Rise?

Stock prices are primarily based on seller supply and buyer demand. But have you ever wondered about what other factors affect a stock's price?

When an analyst changes their opinion of a stock by upgrading or downgrading their rating, it often leads to a sudden stock price adjustment. As of May 01, 2026, there was 1 analyst who downgraded ClearPoint Neuro, Inc.’s stock and 0 analysts who upgraded over the last month.

Additionally, you'll want to evaluate ClearPoint Neuro, Inc.’s financial health and valuation. Investors can use AAII's Value Grade, which combines six key valuation metrics like P/E and P/S ratios for a comprehensive analysis to conduct analysis on ClearPoint Neuro, Inc.’s valuation and financial health. This approach mitigates the limitations of single-metric evaluations.

ClearPoint Neuro, Inc.’s current valuation based on AAII’s Value Grade is a F, which means it is considered to be Ultra Expensive.

Learn how to evaluate stocks with AAII Grades and Scores with A+ Investor today.

Lastly, news and media coverage as well as recent press reports about the company or its industry may cause stock prices to fluctuate. You can check out the most recent news articles about ClearPoint Neuro, Inc. (CLPT) by visiting AAII Stock Evaluator.

Relative Price Strength of ClearPoint Neuro, Inc.

Relative price strength measures a stock's performance against the market, helping investors identify stocks that are outperforming benchmarks.

For AAII’s Momentum Grade, a weighted relative price strength is calculated. Follow this link to learn more about the Momentum Grade.

As of May 01, 2026, ClearPoint Neuro, Inc. has a weighted four-quarter relative price strength of 0.29%, which translates to a Momentum Score of 57 and is considered to be Average.

Want to learn more about how ClearPoint Neuro, Inc. is graded based on AAII’s composite scores for value, growth, quality and earnings estimate revisions? Subscribe to A+ Investor today.

ClearPoint Neuro, Inc. Stock Price: Bottom Line

As of May 4, 2026, ClearPoint Neuro, Inc.’s stock price is $11.500, which is up 1.14% from its previous closing price.

AAII advises against making stock decisions based solely on price or past returns. Instead, consider a variety of metrics, fundamentals, and analytics to evaluate a stock like ClearPoint Neuro, Inc. stock prices are influenced by market supply and demand and offer just a snapshot of a company's overall health.

Subscribing to AAII's A+ Investor provides access to comprehensive analytics and insights for confident investing.